Table 3.
Characteristics of PsA patients by depressive symptoms
| Parameter | No or mild depressive symptoms N = 868 |
Moderate depressive symptoms N = 256 |
Severe depressive symptoms N = 101 |
Total N = 1225 |
|---|---|---|---|---|
| Age, years, mean (SD) | 52.3 ± 12.8 | 51.3 ± 10.9 | 52.8 ± 11.1 | 52.1 ± 12.3 |
| Sex, female, n (%) | 489 (56) | 158 (62) | 72 (71) | 719 (59) |
| Disease duration, years, mean (SD) | 6 ± 7.1 | 6.7 ± 8.3 | 7.8 ± 8.1 | 6.3 ± 7.4 |
| School, ≥ 10 years, n (%) | 680 (80) | 192 (76) | 75 (75) | 947 (79) |
| Currently employed, n (%) | 555 (67) | 155 (65) | 52 (54) | 762 (66) |
| Current smoking, n (%) | 230 (28) | 82 (33) | 37 (37) | 349 (30) |
| Engaging in sports, ≥ 1 h/week, n (%) | 386 (46) | 87 (35) | 29 (29) | 502 (42) |
| Obesity (BMI ≥ 30), n (%) | 304 (36) | 98 (39) | 56 (55) | 458 (38) |
| Comorbidities, 3 or more, n (%) | 247 (29) | 89 (35) | 46 (46) | 382 (31) |
| Depression as known comorbidity, n (%) | 64 (7) | 60 (23) | 25 (25) | 149 (12) |
| Of those, depression treated, n (%) | 44 (69) | 39 (65) | 19 (76) | 102 (68) |
| Fibromyalgia as comorbidity, n (%) | 30 (4) | 21 (8) | 11 (11) | 62 (5) |
| Naive to biologic therapy, n (%) | 442 (60) | 107 (50) | 45 (50) | 594 (57) |
| Systemic glucocorticoids, n (%) | 255 (30) | 92 (36) | 46 (46) | 393 (32) |
| Non-opioid analgesics, n (%) | 92 (12) | 36 (16) | 33 (34) | 161 (15) |
| Opioids, n (%) | 31 (4) | 21 (9) | 15 (16) | 67 (6) |
| CRP ≥ 5 mg/l, n (%) | 314 (41) | 104 (44) | 41 (45) | 459 (42) |
| Tender joint count (0–68), mean (SD) | 6.4 ± 7.7 | 7.2 ± 7.2 | 11.1 ± 10.7 | 6.9 ± 8.0 |
| Swollen joint count (0–66), mean (SD) | 3.0 ± 4.1 | 3.5 ± 4.7 | 4.7 ± 6.2 | 3.3 ± 4.4 |
| Enthesitis, number of sites (0–16), mean (SD) | 2.9 ± 2.5 | 3.6 ± 2.1 | 3.8 ± 3.2 | 3.2 ± 2.5 |
| Nail psoriasis, n (%) | 344 (40) | 103 (40) | 50 (50) | 497 (41) |
| Body surface area, mean (SD) | 8.3 ± 14.6 | 8.9 ± 16.2 | 10.2 ± 17.9 | 8.6 ± 15.2 |
| DAPSA, mean (SD) | 20.6 ± 12.5 | 24.8 ± 12.7 | 32.6 ± 15.9 | 22.5 ± 13.3 |
| Physician global disease activity, NRS 0–10, mean (SD) | 4.9 ± 1.8 | 5.5 ± 1.8 | 6.3 ± 1.6 | 5.1 ± 1.9 |
| Patient global disease activity, NRS 0–10, mean (SD) | 5.2 ± 2.3 | 6.6 ± 2.1 | 8 ± 2 | 5.7 ± 2.4 |
| Patient: DLQI, mean (SD) | 4.9 ± 5.5 | 7.2 ± 6.9 | 9.2 ± 8.2 | 5.8 ± 6.2 |
| Patient: HAQ, mean (SD) | 0.8 ± 0.6 | 1.2 ± 0.6 | 1.6 ± 0.6 | 0.9 ± 0.7 |
| Patient: Fatigue, NRS 0–10, mean (SD) | 4.4 ± 2.2 | 6.8 ± 2.0 | 8.1 ± 1.7 | 5.2 ± 2.7 |
| Patient: Pain, NRS 0–10, mean (SD) | 5 ± 2.3 | 6.4 ± 2.1 | 7.8 ± 1.7 | 5.5 ± 2.4 |
| Patient: Sleep disturbance, NRS 0–10, mean (SD) | 4.2 ± 2.9 | 6.3 ± 2.7 | 7.2 ± 2.7 | 4.9 ± 3.1 |
| Patient: Current work ability, NRS 0–10 (higher is better), mean (SD) | 5.6 ± 2.8 | 3.7 ± 2.7 | 3.5 ± 2.9 | 5 ± 2.9 |
CRP C-reactive protein, DAPSA Disease Activity in Psoriatic Arthritis, DLQI Dermatology Life Quality Index, HAQ Health Assessment Questionnaire, NRS Numerical rating scale